Scarica l'app Stockscreener
3.39
6.87%
-0.25
Pre-mercato:
3.35
-0.04
-1.18%
Precedente Chiudi:
$3.64
Aprire:
$3.7
Volume 24 ore:
3.24M
Relative Volume:
0.61
Capitalizzazione di mercato:
$509.76M
Reddito:
$4.21M
Utile/perdita netta:
$-97.67M
Rapporto P/E:
-3.6452
EPS:
-0.93
Flusso di cassa netto:
$-70.76M
1 W Prestazione:
-1.74%
1M Prestazione:
+20.21%
6M Prestazione:
+21.94%
1 anno Prestazione:
-8.25%
Intervallo 1D:
$3.36
$3.7014
Intervallo di 1 settimana:
$3.36
$4.06
Portata 52W:
$2.01
$6.33
Absci Corp Stock (ABSI) Company Profile
Nome
Absci Corp
Settore
Industria
Telefono
(360) 949-1041
Indirizzo
18105 SE MILL PLAIN BLVD, VANCOUVER
Confronta ABSI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABSI
Absci Corp
|
3.39 | 547.35M | 4.21M | -97.67M | -70.76M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-02 | Iniziato | JP Morgan | Overweight |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-01-22 | Iniziato | Needham | Buy |
| 2024-10-02 | Iniziato | Guggenheim | Buy |
| 2024-07-03 | Iniziato | Morgan Stanley | Overweight |
| 2024-03-14 | Iniziato | Scotiabank | Sector Outperform |
| 2023-12-05 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2023-05-04 | Iniziato | H.C. Wainwright | Buy |
| 2022-08-12 | Downgrade | JP Morgan | Overweight → Underweight |
| 2022-07-18 | Iniziato | Truist | Buy |
| 2022-03-02 | Ripresa | Cowen | Market Perform |
| 2022-02-01 | Iniziato | Berenberg | Buy |
| 2021-11-10 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-08-16 | Iniziato | BofA Securities | Neutral |
| 2021-08-16 | Iniziato | Cowen | Market Perform |
| 2021-08-16 | Iniziato | Credit Suisse | Outperform |
| 2021-08-16 | Iniziato | Stifel | Hold |
Mostra tutto
Absci Corp Borsa (ABSI) Ultime notizie
Truist Financial Maintains Absci Corp(ABSI.US) With Buy Rating - 富途牛牛
Absci (NASDAQ:ABSI) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Absci’s ABS-201 stimulates human hair follicle growth ex vivo - BioWorld MedTech
Independent Director of Absci Picks Up 454% More Stock - Yahoo Finance
Absci’s ABS-201 antibody shows promise for hair regrowth treatment - Investing.com
Absci’s ABS-201 antibody shows promise for hair regrowth treatment By Investing.com - Investing.com Canada
Absci Reports New Human Ex Vivo Data Demonstrating That - GlobeNewswire
Is Absci Poised for a Surge? - StocksToTrade
Absci (NASDAQ:ABSI) Shares Gap UpShould You Buy? - MarketBeat
Absci, former U.S. soccer player Donovan announce partnership - TipRanks
Absci Corporation Partners with Landon Donovan to Address Androgenetic Alopecia and Advance Therapeutic Innovations - Quiver Quantitative
Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research - GlobeNewswire
Absci (NASDAQ:ABSI) Transforms Biotechnology With AI Integration - Kalkine Media
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Is Absci (ABSI) Using ABS-201 To Quietly Prove The Value Of Its AI Drug Engine? - simplywall.st
ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study - The Globe and Mail
Absci (NASDAQ:ABSI) Stock Price Up 10.8%Still a Buy? - MarketBeat
Absci doses first volunteers in phase 1/2a trial of hair loss antibody - Investing.com Nigeria
Absci doses first volunteers in phase 1/2a trial of hair loss antibody By Investing.com - Investing.com South Africa
Absci Stock’s Financial Prospects: An In-Depth Analysis - StocksToTrade
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛
Assessing Absci (ABSI) Valuation After First Volunteers Dosed in ABS-201 HeadLINE Trial - simplywall.st
Absci Corp. Strives for New Horizons Amid Financial Adjustments - timothysykes.com
Absci announces first participants dosed in Phase 1/2a HEADLINE trial - TipRanks
Absci (ABSI): Assessing Valuation as AI‑Designed Hair Loss Drug Enters First Phase 1/2a Trial - Yahoo Finance
Absci Announces First Participants Dosed In Phase 1/2A Headline Trial - TradingView
Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia - The Manila Times
Will Absci Corporation stock deliver shareholder valueJuly 2025 Opening Moves & AI Optimized Trade Strategies - Newser
Absci stock price target raised to $9 from $8 at Jones Trading By Investing.com - Investing.com South Africa
Absci stock price target raised to $9 from $8 at Jones Trading - Investing.com Canada
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $9 - 富途牛牛
Absci Corp. Experiences Revision in Its Stock Evaluation Amid Mixed Financial Performance - Markets Mojo
Will Absci Corporation see short term momentumWeekly Trade Analysis & Risk Controlled Daily Trade Plans - newser.com
How Absci Corporation stock benefits from tech adoptionJuly 2025 Sector Moves & Low Risk High Win Rate Stock Picks - newser.com
Can trapped investors hope for a rebound in Absci CorporationGlobal Markets & Community Shared Stock Ideas - newser.com
Can Absci Corporation stock double in next 5 yearsMarket Growth Report & Expert Approved Momentum Trade Ideas - newser.com
Will Absci Corporation stock maintain growth storyJuly 2025 PreEarnings & High Accuracy Investment Entry Signals - newser.com
Absci Corp’s Earnings Call Highlights Strategic Growth - MSN
Can Absci Corporation stock deliver sustainable ROE2025 Price Action Summary & Momentum Based Trading Ideas - newser.com
Absci (ABSI) Valuation in Focus as Clinical Expansion and Partnership Efforts Gather Pace - Yahoo Finance
Can Absci Corporation stock surprise with earnings upsideJuly 2025 Closing Moves & AI Powered Buy/Sell Recommendations - newser.com
Real time pattern detection on Absci Corporation stockPortfolio Update Summary & Proven Capital Preservation Methods - newser.com
Absci Corporation Advances AI-Driven Therapeutics - MSN
Absci Corp Azioni (ABSI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):